

September 10, 2026
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Results from Study of IV Brincidofovir in Glioblastoma
Accepted for Poster Presentation at the 85th Annual Meeting
of the Japanese Cancer Association**

The study demonstrated brain tumor accumulation and significantly extended survival in a Patient-Derived Xenograft (PDX) model

Tokyo, Japan, September 10, 2026 – SymBio Pharmaceuticals Limited (“SymBio” or the “Company”) today announced that the results of the preclinical study demonstrating the efficacy of intravenous brincidofovir (“IV BCV”) in glioblastoma (“GBM”) have been accepted for poster presentation at the 85th Annual Meeting of the Japanese Cancer Association, to be held from September 24 to 26, 2026, in Kyoto, Japan.

SymBio has been conducting collaborative research with the University of California, San Francisco (“UCSF”) to advance the development of IV BCV in the oncology field. The presentation will report results demonstrating that brincidofovir accumulated in intracranial tumors and that both monotherapy and combination therapy with the standard therapy significantly prolonged survival. These findings represent important evidence that IV BCV may have the potential to be a new therapeutic option for patients with glioblastoma, many of whom do not respond to the current standard therapy. SymBio will continue to advance preparations toward initiating clinical trials.

Details

- **Title:** Elucidation of the preclinical *in vivo* efficacy of brincidofovir against glioblastoma
- **Presenter:** Shoji Nagatani
- **Conference:** The 85th Annual Meeting of the Japanese Cancer Association
- **Date and Time:** 16:40 - 17:25, September 24, 2026
- **Venue:** Kyoto International Conference Center, Kyoto, Japan
- **Presentation Number:** P-1233

Statement from Shoji Nagatani of the Translational Research Department at SymBio: “Demonstrating the efficacy of IV BCV using a patient-derived xenograft (PDX) intracranial implantation model that closely recapitulates patients’ tumor characteristics is an important achievement. We are confident that these findings will provide significant momentum toward the clinical application of IV BCV.”

The Company does not expect this matter to have a material impact on its consolidated financial results for the fiscal year ending December 2026.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125

Notes

Glioma

Gliomas are brain tumors that arise from glial cells. They progress very rapidly, have a poor prognosis, and are associated with a high mortality rate. Glioblastoma, the most malignant grade 4 subtype, has a median survival of only two to 18 months following diagnosis, and a five-year survival rate of 5% or less. Cancers with a five-year survival rate of 50% or less are classified as “refractory cancers.” Glioblastoma, one such refractory cancer, is estimated to affect approximately 2,300 patients annually in Japan and approximately 28,000 patients annually in Europe and the United States. The current standard therapy combines temozolomide (brand name: Temodar®) with radiotherapy. However, nearly half of patients develop resistance to temozolomide, the standard therapy. As no treatment has yet been established to overcome this resistance, there is a strong need for the development of new therapies.

About SymBio : BCV Business Strategy Based on Three Therapeutic Pillars

Since obtaining the global license for BCV in September 2019, SymBio has advanced collaborative research with world-class institutions to unlock IV BCV's potential across three strategic therapeutic areas where the Company is currently focusing its development resources: (1) viral infections following hematopoietic stem cell transplantation; (2) solid tumors; and (3) neurodegenerative diseases. By concentrating management resources on these therapeutic areas and actively pursuing global business expansion, SymBio aims to maximize the business value of BCV.